Similarly, the increase in SETD1A expression in tamoxifen-resistant cells seems to be the result of the dominant survival of resistant clones, CSCs, expressing high levels of SETD1A and SOX2 due to intra-tumor heterogeneity in primary BC. The gene discussed is SETD1A; the disease is neoplasm.